Adulthood olanzapine treatment fails to alleviate decreases of ChAT and BDNF RNA expression in rats quinpirole-primed as neonates

Brain Research

Volumn 1200, Issue , 2008, Pages 66-77

  Brown, Russell W ^a   Perna, Marla K ^a   Maple, Amanda M ^a   Wilson, Tracy D ^b   Miller, Barney E ^b  

^a EAST TENNESSEE STATE UNIVERSITY   (United States)

^b East Tennessee State University   (United States)

Author keywords

D2 receptor; Development; Morris water maze; Neonatal; Olanzapine; Quantifiable PCR; Quinpirole; Rat

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLINE ACETYLTRANSFERASE; DOPAMINE 2 RECEPTOR; MESSENGER RNA; NERVE GROWTH FACTOR; OLANZAPINE; QUINPIROLE;

ADULTHOOD; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; BRAIN TISSUE; CEREBELLUM; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; GENE EXPRESSION REGULATION; HIPPOCAMPUS; LIFESPAN; MALE; MAZE TEST; MENTAL PERFORMANCE; NEWBORN; NEWBORN PERIOD; NONHUMAN; NUCLEOTIDE SEQUENCE; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR SENSITIVITY; SPRAGUE DAWLEY RAT; SWIMMING; TASK PERFORMANCE; YAWNING;

ACETYLCHOLINE; AGING; ANIMALS; ANIMALS, NEWBORN; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHOLINE O-ACETYLTRANSFERASE; COGNITION; COGNITION DISORDERS; DOPAMINE AGONISTS; DOWN-REGULATION; FEMALE; HIPPOCAMPUS; LEARNING DISORDERS; MALE; MAZE LEARNING; QUINPIROLE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RNA, MESSENGER; TIME;

ANIMALIA; RATTUS;

EID: 40849141930     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2008.01.041     Document Type: Article

References (76)

1. Andersson C., Hamer R.M., Lawler C.P., Mailman R.B., and Lieberman J.A. Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs. Neuropsychopharmacology 27 (2002) 143-151
2. Angelucci F., Aloe L., Iannitelli A., Gruber S.H., and Mathe A.A. Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain. Eur. Neuropsychopharmacol. 15 (2005) 311-317
3. Bai O., Chlan-Fourney J., Bowen R., Keegan D., and Li X.M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J. Neurosci. Res. 71 (2003) 127-131
4. Barmack N.H., Baughman R.W., and Eckenstein F.P. Cholinergic innervation of the cerebellum of the rat by secondary vestibular afferents. Ann. N. Y. Acad. Sci. 656 (1992) 566-579
5. Barmack N.H., Baughman R.W., Eckenstein F.P., and Shojaku H. Secondary vestibular cholinergic projection to the cerebellum of rabbit and rat as revealed by choline acetyltransferase immunohistochemistry, retrograde and orthograde tracers. J. Comp. Neurol. 317 (1992) 250-270
6. Berger-Sweeney J., Stearns N.A., Murg S.L., Floerke-Nashner L.R., Lappi D.A., and Baxter M.G. Selective immunolesions of cholinergic neurons in mice: effects on neuroanatomy, neurochemistry, and behavior. J. Neurosci. 21 (2001) 8164-8173
7. Brown R.W., Thompson K.N., Click I.A., Best R.A., Thacker S.K., and Perna M.K. The effects of eticlopride on Morris water task performance in male and female rats neonatally treated with quinpirole. Psychopharmacology 180 (2005) 234-240
8. Brown R.W., Flanigan T.J., Thompson K.N., Thacker S.K., Schaefer T.L., and Williams M.T. Neonatal quinpirole treatment impairs Morris water task performance in early postweanling rats: relationship to increases in corticosteron and decreases in neurotrophic factors. Biol. Psychiatry 56 (2004) 161-168
9. Brown R.W., Flanigan T.J., Thompson K.N., Thacker S.K., Schaefer T.L., and Williams M.T. Adulthood nicotine treatment alleviates behavioural impairments in rats neonatally treated with quinpirole: possible roles of acetylcholine function and neurotrophic factor expression. Eur. J. Neurosci. 19 (2004) 1634-1642
10. Brown R.W., Gass J.T., and Kostrzewa R.M. Neonatal quinpirole treatments produce spatial memory deficits and enhance skilled reaching in adult rats. Pharmacol. Biochem. Behav. 72 (2002) 591-600
11. Brown R.W., Gonzalez C.L., and Kolb B. Nicotine improves Morris water task performance in rats given medial frontal cortex lesions. Pharmacol. Biochem. Behav. 67 (2000) 473-478
12. Castaneda E., Becker J.B., and Robinson T.E. The long-term effects of repeated amphetamine treatment in vivo on amphetamine, KCl and electrical stimulation evoked striatal dopamine release in vitro. Life Sci. 42 (1988) 2447-2456
13. Chen H., Parker S.L., Matta S.G., and Sharp B.M. Gesttational nicotine exposure reduces nicotinic cholinergic receptor (nAChR) expression in dopaminergic brain regions of adolescent rats. Eur. J. Neurosci. 22 (2005) 380-388
14. Chlan-Fourney J., Ashe P., Nylen K., Juorio A.V., and Li X.M. Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Res. 954 (2002) 11-20
15. Cooper S.J., Rusk I.N., and Barber D.J. Yawning induced by the selective dopamine D2 agonist N-0437 is blocked by the selective dopamine autoreceptor antagonist (+)-UH 232. Physiol. Behav. 45 (1989) 1263-1266
16. Crow T.J. Schizophrenia: the nature of the psychological disturbance and its possible neurochemcial basis. Ciba Found. Symp. 69 (1979) 335-343
17. Davis K.L., Kahn R.S., Ko G., and Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatr. 148 (1991) 1474-1486
18. Day J.C., and Fibiger H.C. Dopaminergic regulation of septohippocampal cholinergic neurons. J. Neurochem. 63 (1994) 2086-2092
19. Dekker A.J., Gage F.H., and Thal L.J. Delayed treatment with nerve growth factor improves acquisition of a spatial task in rats with lesions of the nucleus basalis magnocellularis: evaluation of the involvement of different neurotransmitter systems. Neuroscience 48 (1992) 111-119
20. Didriksen M., Kreilgaard M., and Arnt J. Sertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatment. Eur. J. Pharmacol. 542 (2006) 108-116
21. Durany N., Michel T., Zochling R., Boissl K.W., Cruz-Sanchez F.F., Riederer P., and Thome J. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr. Res. 52 (2001) 79-86
22. Eguibar J.R., Romero-Carbente J.C., and Moyaho A. Behavioral differences between selectively bred rats: D1 versus D2 receptors in yawning and grooming. Pharmacol. Biochem. Behav. 74 (2003) 827-832
23. Elvevag B., and Goldberg T.E. Cognitive impairment in schizophrenia is the core of the disorder. Crit. Rev. Neurobiol. 14 (2000) 1-2
24. French S.J., Humby T., Horner C.H., Sofroniew M.V., and Rattray M. Hippocampal neurotrophin and trk receptor mRNA levels are altered by local administration of nicotine, carbachol and pilocarpine. Brain Res. Mol. Brain Res. 67 (1999) 124-136
25. Frey U., Matthies H., Reymann K.G., and Matthies H. The effect of dopaminergic D1 receptor blockade during tetanization on the expression of long-term potentiation in the rat CA1 region in vitro. Neurosci. Lett. 129 (1991) 111-114
26. Fujishiro H., Umegaki H., Suzuki Y., Oohara-Kurotani S., Yamaguchi Y., and Iguchi A. Dopamine D2 receptor plays a role in memory function: implications of dopamine-acetylcholine interaction in the ventral hippocampus. Psychopharmacology 182 (2005) 253-256
27. Goldberg T.E., Goldman R.S., Burdick K.E., Malhotra A.K., Lencz T., Patel R.C., Woerner M.G., Schooler N.R., Kane J.M., and Robinson D.G. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?. Arch. Gen. Psychiatry 64 (2007) 1115-1122
28. Gonzalez C.L., Kolb B., and Whishaw I.Q. A cautionary note regarding drug and brain lesion studies that use swimming pool tasks: partial reinforcement impairs acquisition of place learning in a swimming pool but not on dry land. Behav. Brain Res. 12 (2000) 43-52
29. Hannesson D.K., and Skelton R.W. Recovery of spatial performance in the Morris water maze following bilateral transection of the fimbria/fornix in rats. Behav. Brain Res. 90 (1998) 35-56
30. Healy S.D., Braham S.R., and Braithwaite V.A. Spatial working memory in rats: no differences between the sexes. Proc. Biol. Sci. 266 (1999) 2303-2308
31. Holson R.R., and Pearce B. Principles and pitfalls in the analysis of prenatal treatment effects in multiparous species. Neurotoxicol. Teratol. 14 (1992) 221-228
32. Horacek J., Bubenikova-Valesova V., Kopecek M., Palenicek T., Dockery C., Mohr P., and Hoschl C. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20 (2006) 389-409
33. Imperato A., Obinu M.C., and Gessa G.L. Stimulation of both dopamine D1 and D2 receptors facilitates in vivo acetylcholine release in the hippocampus. Brain Res. 618 (1993) 341-345
34. Jaarsma D., Ruigrok T.J., Caffe R., Cozzari C., Levey A.I., Mugnaini E., and Voogd J. Cholinergic innervation and receptors in the cerebellum. Prog. Brain Res. 114 (1997) 67-96
35. Johnson D.E., Nedza F.M., Spracklin D.K., Ward K.M., Schmidt A.W., Iredale P.A., Godek D.M., and Rollema H. The role of muscarinic receptor antagonism in antipsychotic-induced hippocampal acetylcholine release. Eur. J. Pharmacol. 506 (2005) 209-219
36. Julien R.M. A primer of drug action (2003), Worth, New York, NY
37. Kapur S., and Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu. Rev. Med. 52 (2001) 503-517
38. Kokkinidis L., and Anisman H. Amphetamine models of paranoid schizophrenia: an overview and elaboration of animal experimentation. Psychol. Bull. 88 (1980) 551-579
39. Kostrzewa R.M. Dopamine receptor supersensitivity. Neurosci. Biobehav. Rev. 19 (1995) 1-17
40. Kostrzewa R.M., and Brus R. Neonatal homogulus supersensitization of quinpirole-induced yawning in rats. Pharm. Biochem. Behav. 39 (1991) 39-50
41. Kostrzewa R.M., Kostrzewa J.P., Nowak P., Kostrzewa R.A., and Brus R. Dopamine D2 agonist priming in intact and dopamine-lesioned rats. Neurotox. Res. 6 (2004) 457-462
42. Kostrzewa R.M., Guo J., and Kostrzewa F.P. Neonatal quinpirole treatment induces vertical jumping activity in rats. Eur. J. Pharmacol. 239 (1993) 183-187
43. Lessmann V., Gottmann K., and Malcangio M. Neurotrophin secretion: current facts and future prospects. Prog. Neurobiol. 69 (2003) 341-374
44. Levin E.D., Petro A., and Beatty A. Olanzapine interactions with nicotine and mecamylamine in rats: effects on memory function. Neurotoxicol. Teratol. 27 (2005) 459-464
45. Levine E.S., Crozier R.A., Black I.B., and Plummer M.R. Brain-derived neurotrophic factor modulates hippocampal synaptic transmission by increasing N-methyl-d-aspartic acid receptor activity. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 10235-10239
46. Lukoyanov N.V., Pereira P.A., Paula-Barbosa M.M., and Cadete-Leite A. Nerve growth factor improves spatial learning and restores hippocampal cholinergic fibers in rats withdrawn from chronic treatment with ethanol. Exp. Brain Res. 148 (2003) 88-94
47. Mancama D., Mata I., Kerwin R.W., and Arranz M.J. Choline acetyltransferase variants and their influence in schizophrenia and olanzapine response. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 144 7 (2007) 849-853
48. Maple A.M., Perna M.K., Parlaman J.P., Stanwood G.D., and Brown R.W. Ontogenetic quinpirole treatment produces long-lasting decreases in the expression of Rgs9, but increases Rgs17 in the striatum, nucleus accumbens and frontal cortex. Eur. J. Neurosci. 26 (2007) 2532-2538
49. Nava F., Carta G., Battasi A.M., and Gessa G.L. D (2) dopamine receptors enable delta (9) -tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration. Br. J. Pharmacol. 130 (2000) 1201-1210
50. Nowak P., Brus R., and Kostrzewa R.M. Amphetamine-induced enhancement of neostriatal in vivo microdialysate dopamine content in rats, quinpirole-primed as neonates. Pol. J. Pharmacol. 53 (2001) 319-329
51. Otmakhova N.A., and Lisman J.E. Dopamine selectively inhibits the direct cortical pathway to the CA1 hippocampal region. J. Neurosci. 19 (1999) 1437-1445
52. Parikh V., Khan M.M., Terry A., and Mahadik S.P. Differential effects of typical and atypical antipsychotics on nerve growth factor and choline acetyltransferase expression in the cortex and nucleus basalis of rats. J. Psychiatr. Res. 38 (2004) 521-529
53. Pirondi S., D'Intino G., Gusciglio M., Massella A., Giardino L., Kuteeva E., Ogren S.O., Hokfelt T., and Calza L. Changes in brain cholinergic markers and spatial learning in old galanin-overexpressing mice. Brain Res. 1138 (2007) 10-20
54. Pisani A., Bonsi P., Centonze D., Calabresi P., and Bernardi G. Activation of D2-like dopamine receptors reduces synaptic inputs to striatal cholinergic interneurons. J. Neurosci. 20 (2000) RC69
55. Reilly J.L., Harris M.S., Khine T.T., Keshavan M.S., and Sweeney J.A. Antipsychotic drugs exacerbate impairment on a working memory task in first-episode schizophrenia. Biol. Psychiatry 62 (2007) 818-824
56. Riedel, M., Müller. N., Spellmann, I., Engel, R.R., Musil, R., Valdevit, R., Dehning, S., Douhet, A., Cerovecki, A., Strassnig, M., Möller, H.J., in press. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. Jul 14 [Electronic publication ahead of print].
57. Roof R.L., and Stein D.G. Gender differences in Morris water maze performance depend on task parameters. Physiol. Behav. 68 (1999) 81-86
58. Sanchez C., and Arnt J. In-vivo assessment of 5-HT2A and 5-HT2C antagonistic properties of newer antipsychotics. Behav. Pharmacol. 11 (2000) 291-298
59. Schaaf M.J., Workel J.O., Lesscher H.M., Vreugdenhil E., Oitzl M.S., and de Kloet E.R. Correlation between hippocampal BDNF mRNA expression and memory performance in senescent rats. Brain Res. 915 (2001) 227-233
60. Seeman P., Ko F., Jack E., Greenstein R., and Dean B. Consistent with dopamine supersensitivity, RGS9 expression is diminished in the amphetamine-treated animal model of schizophrenia and in post-mortem schizophrenia brain. Synapse 61 (2007) 303-309
61. Seeman P., Schwarz J., Chen J.F., Szechtman H., Perreault M., McKnight G.S., Roder J.C., Quirion R., Boksa P., Srivastava L.K., Yanai K., Weinshenker D., and Sumiyoshi T. Psychosis pathways converge via D2high dopamine receptors. Synapse 60 (2006) 319-314
62. Shirazi-Southall S., Rodriguez D.E., and Nomikos G.G. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacol 26 (2002) 583-594
63. Terry Jr. A.V., Gearhart D.A., Mahadik S.P., Warsi S., Davis L.W., and Waller J.L. Chronic exposure to typical or atypical antipsychotics in rodents: temporal effects on central alpha7 nicotinic acetylcholine receptors. Neuroscience 136 (2005) 519-529
64. Terry Jr. A.V., Gearhart D.A., Mahadik S.P., Warsi S., and Waller J.L. Chronic treatment with first or second-generation antipsychotics in rodents: effects on high affinity nicotinic and muscarinic acetylcholine receptors in the brain. Neuroscience 140 (2006) 1277-1287
65. Thacker S.K., Perna M.K., Ward J.J., Schaefer T.L., Williams M.T., Kostrzewa R.M., and Brown R.W. The effects of adulthood olanzapine treatment on cognitive performance and neurotrophic factor content in male and female rats neonatally treated with quinpirole. Eur. J. Neurosci. 24 (2006) 2075-2083
66. Tollefson G.D. Cognitive function in schizophrenic patients. J. Clin. Psychiatry 57 Suppl 11 (1996) 31-39
67. Toyooka K., Asama K., Watanabe Y., Muratake T., Takahashi M., Someya T., and Nawa H. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res. 110 3 (2002) 249-257 Jul 31
68. Tzavara E.T., Bymaster F.P., and Nomikos G.G. The procholinergic effects of the atypical antipsychotic olanzapine are independent of muscarinic autoreceptor inhibition. Mol. Psychiatry 11 (2006) 619-621
69. Umegaki H., Munoz J., Meyer R.C., Spangler E.L., Yoshimura J., Ikari H., Iguchi A., and Ingram D.K. Involvement of dopamine D(2) receptors in complex maze learning and acetylcholine release in ventral hippocampus of rats. Neuroscience 103 (2001) 27-33
70. Weiss T., Veh R.W., and Heinemann U. Dopamine depresses cholinergic oscillatory network activity in rat hippocampus. Eur. J. Neurosci. 18 (2003) 2573-2580
71. Woodward N.D., Purdon S.E., Meltzer H.Y., and Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 8 (2005) 457-472
72. Van der Zee C.E., Lourenssen S., Stanisz J., and Diamond J. NGF deprivation of adult rat brain results in cholinergic hypofunction and selective impairments in spatial learning. Eur. J. Neurosci. 7 (1995) 160-168
73. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., and Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3 (2002) RESEARCH0034
74. Wei Z., Bai O., Richardson J.S., Mousseau D.D., and Li X.M. Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. J. Neurosci. Res. 73 (2003) 364-368
75. Yanagihashi R., and Ishikawa T. Studies on long-term potentiation of the population spike component of hippocampal field potential by the tetanic stimulation of the perforant path rats: effects of a dopamine agonist, SKF-38393. Brain Res. 579 (1992) 79-86
76. Zou L., Yuan X., Long Y., Shine H.D., and Yang K. Improvement of spatial learning and memory after adenovirus-mediated transfer of the nerve growth factor gene to aged rat brain. Hum. Gene Ther. 13 (2002) 2173-2184